{"publisher":"Oral GLP-1 Direct","product":"Oral GLP-1 treatments","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"The June 2026 US Wegovy label includes oral tablets for long-term adult weight reduction and cardiovascular risk reduction in specified adults, with diet and physical activity.","href":"https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"label":"Research finding 2","text":"Wegovy tablets are swallowed whole and have empty-stomach and post-dose waiting requirements in their own label.","href":"https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"label":"Research finding 3","text":"OASIS4 randomized 307 adults without diabetes; at week 64 mean weight change was−13.6% with the 25 mg daily trial tablet versus−2.2% with placebo.","href":"https://pubmed.ncbi.nlm.nih.gov/40934115/"},{"label":"Research finding 4","text":"OASIS4 gastrointestinal adverse events occurred in 74.0% with the oral tablet versus 42.2% with placebo.","href":"https://pubmed.ncbi.nlm.nih.gov/40934115/"}],"sources":[{"title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.","href":"https://pubmed.ncbi.nlm.nih.gov/40934115/"},{"title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.","href":"https://pubmed.ncbi.nlm.nih.gov/31186300/"},{"title":"WEGOVY (semaglutide) injection and tablets: full prescribing information, revised June2026","href":"https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"title":"FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss","href":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"guides":[{"title":"Semaglutide tablets, drops and lozenges: ask for formulation-specific evidence","url":"https://oralglp1direct.com/research-guides/approved-tablets-versus-drops-lozenges","description":"A guide to separating approved oral products from compounded preparations and unsupported evidence transfers.","date":"2026-11-07"},{"title":"Food, water and other tablets: build the routine around the exact product","url":"https://oralglp1direct.com/research-guides/food-water-daily-tablet-routine","description":"Why oral semaglutide and Foundayo need separate administration checklists, with practical questions for a pharmacist.","date":"2026-11-07"},{"title":"Medication review before an oral GLP-1 switch","url":"https://oralglp1direct.com/research-guides/medication-review-switching-oral-glp1","description":"Prepare the product history, interaction questions and written handoff needed before changing an oral GLP-1 medicine.","date":"2026-11-07"},{"title":"Oral semaglutide and physical function: look beyond the scale","url":"https://oralglp1direct.com/research-guides/oasis-four-physical-function-outcomes","description":"Understand OASIS 4’s patient-reported physical-function endpoint and how to discuss meaningful daily-life goals.","date":"2026-11-07"},{"title":"Why oral GLP-1 trial percentages do not form a ranking","url":"https://oralglp1direct.com/research-guides/oral-glp1-trial-comparisons","description":"Read OASIS, PIONEER and ATTAIN results by population, dose, comparator and analysis before comparing products.","date":"2026-11-07"},{"title":"Why oral semaglutide depends on its formulation","url":"https://oralglp1direct.com/research-guides/oral-semaglutide-absorption-snac","description":"Understand SNAC, exposure and why a tablet study cannot validate an unrelated oral preparation.","date":"2026-11-07"},{"title":"Oral semaglutide and liver impairment: drug exposure is not liver-treatment efficacy","url":"https://oralglp1direct.com/research-guides/oral-semaglutide-hepatic-impairment-pharmacokinetics","description":"A pharmacokinetic study answers a different question from a MASH trial or a long-term safety study.","date":"2026-11-07"},{"title":"Oral GLP-1 medicines are not all the same kind of molecule","url":"https://oralglp1direct.com/research-guides/peptide-tablets-small-molecule-glp1","description":"Compare peptide semaglutide tablets and small-molecule orforglipron by product, indication and daily routine.","date":"2026-11-07"},{"title":"Oral semaglutide alongside insulin: an add-on study is not a replacement plan","url":"https://oralglp1direct.com/research-guides/pioneer-eight-oral-semaglutide-with-insulin","description":"Understand PIONEER 8’s combination-treatment question and the clinical handoff needed before changing an insulin-based plan.","date":"2026-11-07"},{"title":"Oral semaglutide with reduced kidney function: what PIONEER 5 tested","url":"https://oralglp1direct.com/research-guides/pioneer-five-moderate-renal-impairment","description":"Distinguish glucose-control evidence in moderate renal impairment from a long-term kidney-outcome claim.","date":"2026-11-07"},{"title":"Tablet versus injection: what the liraglutide comparison actually established","url":"https://oralglp1direct.com/research-guides/pioneer-four-tablet-versus-liraglutide","description":"Read PIONEER 4’s noninferiority result without turning one direct comparison into a verdict on all oral and injectable GLP-1 medicines.","date":"2026-11-07"},{"title":"Oral semaglutide versus sitagliptin: make the comparison match the goal","url":"https://oralglp1direct.com/research-guides/pioneer-three-sitagliptin-active-comparison","description":"PIONEER 3 provides a direct tablet comparison in a defined diabetes population, with separate glucose, weight and tolerability questions.","date":"2026-11-07"}]}